This inventor holds 10 USPTO granted patents and 9 published patent applications. Top assignees: Alcon, Inc., Novartis Ag, University of Iowa Research Foundation. Active years: 2006-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
6 out of 1,306 
2 out of 3,975 
2 out of 925 
Years Active: 2006-2017
Title: Loretta Graves McNatt: Innovator in Glaucoma Treatment
Introduction
Loretta Graves McNatt is a distinguished inventor based in Hurst, Texas. She has made significant contributions to the field of medical science, particularly in the treatment of glaucoma. With a total of 10 patents to her name, McNatt has established herself as a leading figure in her area of expertise.
Latest Patents
Among her latest patents is the innovative approach titled "RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma." This patent focuses on utilizing RNA interference to inhibit Frizzled Related Protein-1 mRNA expression. It is particularly aimed at treating patients who have glaucoma or are at risk of developing this condition. This groundbreaking work highlights her commitment to advancing medical treatments.
Career Highlights
Throughout her career, McNatt has worked with prominent companies such as Alcon, Inc. and Novartis AG. Her experience in these organizations has allowed her to collaborate with some of the brightest minds in the industry.
Collaborations
Some of her notable coworkers include Abbot F. Clark and Wan-Heng Wang. Their collaborative efforts have contributed to the success of her innovative projects.
Conclusion
Loretta Graves McNatt's work in the field of glaucoma treatment exemplifies her dedication to innovation and medical advancement. Her patents and collaborations reflect her significant impact on healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile